Filtered By:
Condition: Overactive Bladder Syndrome
Countries: Sweden Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
ConclusionsThis large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.
Source: Drug Safety - August 1, 2021 Category: Drugs & Pharmacology Source Type: research
